Amphastar PharmaceuticalsAMPH -4.91%83 Return-on-Tangible-Equity is 11.76% as of Mar. 2026, which is 26% below its 10-year median of 15.85. GuruFocus rates AMPH with a GF Score™ of 83/100 and a GF Value™ of $48.79 (Significantly Undervalued). The stock has 5 warning signs investors should review. Among 896 Drug Manufacturers companies, Amphastar Pharmaceuticals ranks better than 90.07% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Amphastar Pharmaceuticals's annualized net income for the quarter that ended in Mar. 2026 was $25.7 Mil. Amphastar Pharmaceuticals's average shareholder tangible equity for the quarter that ended in Mar. 2026 was $218.3 Mil. Therefore, Amphastar Pharmaceuticals's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 11.76%.
The historical rank and industry rank for Amphastar Pharmaceuticals's Return-on-Tangible-Equity or its related term are showing as below:
AMPH'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -1.98 Med: 15.85 Max: 190.17
Current: 40.14
During the past 13 years, Amphastar Pharmaceuticals's highest Return-on-Tangible-Equity was 190.17%. The lowest was -1.98%. And the median was 15.85%.
AMPH's Return-on-Tangible-Equity is ranked better than 90.07% of 896
companies
in the Drug Manufacturers industry
Industry Median: 7.795
vs AMPH: 40.14
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Amphastar Pharmaceuticals Return-on-Tangible-Equity Related Terms
Amphastar Pharmaceuticals Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Amphastar Pharmaceuticals's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AMPH vs ETON, PCRX, BIOA: Return-on-Tangible-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Amphastar Pharmaceuticals's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Amphastar Pharmaceuticals Return-on-Tangible-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Amphastar Pharmaceuticals's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Amphastar Pharmaceuticals's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 11.76% mean?
Amphastar Pharmaceuticals (AMPH) has a Return-on-Tangible-Equity of 11.76% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Amphastar Pharmaceuticals and its competitors. This is 26% below median its historical median of 15.85. According to the industry distribution chart, Amphastar Pharmaceuticals ranks #89 out of 896 companies in the Drug Manufacturers industry, placing it in the top 9.9%.
Is Amphastar Pharmaceuticals' Return-on-Tangible-Equity too high?
Amphastar Pharmaceuticals' current Return-on-Tangible-Equity of 11.76% is 26% below median its 10-year median of 15.85. The Drug Manufacturers industry median Return-on-Tangible-Equity is 7.80. Amphastar Pharmaceuticals' value of 11.76% is 50.9% above this industry median. Based on the distribution chart, Amphastar Pharmaceuticals ranks #89 out of 896 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Amphastar Pharmaceuticals has a GF Score™ of 83/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Amphastar Pharmaceuticals' Return-on-Tangible-Equity compare to ETON and PCRX?
According to the Drug Manufacturers industry distribution chart, Amphastar Pharmaceuticals ranks #89 out of 896 companies for Return-on-Tangible-Equity. This places Amphastar Pharmaceuticals in the top 10% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Equity is 7.80. Amphastar Pharmaceuticals' value of 11.76% is 50.9% above this benchmark. While the company's 10-year median is 15.85 vs. the industry median of 7.80, Amphastar Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Drug Manufacturers company?
The median Return-on-Tangible-Equity among Drug Manufacturers companies is 7.80, based on 896 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Amphastar Pharmaceuticals's current Return-on-Tangible-Equity of 11.76% is 50.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Amphastar Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Equity is 7.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Amphastar Pharmaceuticals's current Return-on-Tangible-Equity is 11.76%, which is 26% below median its own 10-year median of 15.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amphastar Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Amphastar Pharmaceuticals (AMPH) is currently considered Significantly Undervalued. The stock's GF Value™ is $48.79, compared to a current price of $20.71 — trading 57.6% below its estimated fair value. The current Return-on-Tangible-Equity is 11.76%, which is 26% below median its 10-year median of 15.85 and 50.9% above the Drug Manufacturers industry median of 7.80. Amphastar Pharmaceuticals' overall GF Score™ is 83/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Amphastar Pharmaceuticals (AMPH), the current Return-on-Tangible-Equity is 11.76% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Amphastar Pharmaceuticals (AMPH) Overvalued in 2026?
Based on GuruFocus' analysis, Amphastar Pharmaceuticals stock appears to be undervalued.
The current stock price of $20.71 is trading 57.6% below its estimated GF Value™ of $48.79.
GuruFocus considers Amphastar Pharmaceuticals to be Significantly Undervalued.
Key valuation signals for AMPH:
Return-on-Tangible-Equity: 11.76% (26% below median its 10-year median of 15.85)
GF Value™: $48.79 vs. price of $20.71 (57.6% below fair value)
Industry Position: 50.9% above the Drug Manufacturers median (#89 of 896)
No single metric tells the full story. See the AMPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient (or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment: pharmaceutical products. Geographically, the business presence of the firm is seen in the United States, China, and France, of which the U.S. accounts for the majority of the revenue.
83GF Score
Get the complete analysis for AMPH
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AMPH has been successfully added to your 
